A "possible link" exists between AstraZeneca's coronavirus vaccine and rare blood clots, according to the European Union's top drug regulator, but the benefits of the drug still outweigh its risks.
It is also the main shot being used by Covax, the global program to deliver vaccines to low- and middle-income countries.
The World Health Organization, the U.K.’s medicines regulator and the International Society on Thrombosis and Hemostasis have all said that the benefits of the vaccine outweigh the risks.
AstraZeneca has previously said its studies have found no higher risk of blood clots as a result of its vaccine.
— Updated at 11:01 a.m.